Relenza

GPTKB entity

Statements (57)
Predicate Object
gptkbp:instance_of gptkb:immunotherapy
gptkbp:approves gptkb:1999
gptkb:FDA
gptkbp:atccode J05 AH01
gptkbp:availability pharmacies
prescription only
gptkbp:bioavailability not applicable
gptkbp:casnumber 139110-80-8
gptkbp:clinical_trial Phase III
ongoing studies for efficacy
gptkbp:clinical_use pandemic influenza
seasonal influenza
gptkbp:contraindication history of asthma
children under 5 years
history of COPD
gptkbp:developed_by gptkb:Glaxo_Smith_Kline
gptkbp:dosage_form inhalation powder
gptkbp:drug_interactions may interact with other antiviral drugs
gptkbp:excretion urine
gptkbp:formulation dry powder inhaler
powder for inhalation
https://www.w3.org/2000/01/rdf-schema#label Relenza
gptkbp:indication prophylaxis of influenza
gptkbp:ingredients gptkb:zanamivir
gptkbp:invention patented
gptkbp:lifespan 2.5 to 5 hours
gptkbp:marketed_as gptkb:Relenza
multiple countries
gptkbp:mechanism_of_action neuraminidase inhibitor
gptkbp:metabolism minimal hepatic metabolism
gptkbp:name essential medicines
gptkbp:packaging blister packs
gptkbp:patient_education instruct on proper inhalation technique
gptkbp:patient_population adults and children
gptkbp:price varies by region
gptkbp:provides_guidance_on CDC recommends use during outbreaks
WHO recommends use during pandemics
gptkbp:requires available online
gptkbp:research investigated for other viral infections
gptkbp:research_focus influenza resistance
gptkbp:route_of_administration inhalation
gptkbp:safety_features generally well tolerated
gptkbp:safety_measures monitor for respiratory issues
gptkbp:shelf_life 3 years
gptkbp:side_effect headache
nausea
allergic reactions
cough
bronchospasm
throat irritation
neuropsychiatric events
gptkbp:storage store at room temperature
gptkbp:structure C12 H20 N4 O7 S
gptkbp:trade gptkb:zanamivir
gptkbp:used_for treatment of influenza
gptkbp:bfsParent gptkb:zanamivir
gptkbp:bfsLayer 5